Jason Karlawish
speaker
1,378 appearances
5 recordings
1 series
first heard Feb 2021
last heard Dec 2023
Jason Karlawish’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsNo recordings in the last 12 months.Older appearances are listed below; set an alert to hear about the next one.
Appearances
Вел асоціативи фор статус іфа.
Uh uh one copy of ApoE raises your risk, two copies increases it more.
And maybe we should talk more about this risk.
What do you guys think?
Yeah, so um the the risk that's most concerning is area uh is the edema, the swelling.
That's what causes symptoms and uh if not caught disability.
And in uh Lacanomab there were deaths and in DanaMab there were deaths.
Three each, right?
Three in
That's correct, right.
So ape in so Aria E is Aria, Aria, ape hemorrhage and edema is very common.
About fifty percent of ApoE homozygotes in the lecanomab study had that.
Uh aria with edema is not as common.
About two percent of E four homozygotes had it.
And then serious aria for w any E4 carriage was about three percent.
Um so it's a com aria is common, often it's not symptomatic and not a problem, but it requires being detected because if you don't detect it, it can become symptomatic and a problem.
So in the studies
It required either dose adjustment or dose cessation.
Um, but many continued if all they had was RAH
low grade RAE andor got resumed on dose.
Showing 241–260 of 1,378 · page 13 of 69
← Previous
Next →